Treatment of Refractory and Relapsed Hodgkin's Lymphoma: Facts and Perspectives

Haematologica - Italy
doi 10.3324/haematol.11130
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie
Oncology
2016English

Prognostic Value of Comorbidity for Auto-SCT Eligibility and Outcome in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Bone Marrow Transplantation
TransplantationHematology
2010English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

LACE-conditioned Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin's Lymphoma: Treatment Outcome and Risk Factor Analysis in 67 Patients From a Single Centre

Bone Marrow Transplantation
TransplantationHematology
2006English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology
Oncology
2019English

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

Malignant tumours
2017English

Treating Hodgkin Lymphoma in the New Millennium: Relapsed and Refractory Disease

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy